Effects of the Allosteric Modification of Hemoglobin on Brain Oxygen and Infarct Size in a Feline Model of Stroke
- 1 August 1997
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 28 (8) , 1624-1630
- https://doi.org/10.1161/01.str.28.8.1624
Abstract
Cerebral ischemia and stroke are leading causes of morbidity and mortality. An approach to protecting the brain during ischemia is to try to increase the delivery of oxygen via the residual blood flow through and around ischemic tissue. To test this hypothesis, we used a novel oxygen delivery agent, RSR-13 (2-[4-[[(3,5-dimethylanilino)-carbonyl]-methyl]phenoxy]-2-methylpr opionic acid). Intravenous administration of RSR-13 increases oxygen delivery through allosteric modification of the hemoglobin molecule, resulting in a shift in the hemoglobin/oxygen dissociation curve in favour of oxygen delivery. We studied RSR-13 in a feline model of permanent middle cerebral artery occlusion to assess its effects on cerebral oxygenation and infarct size. A randomized, blinded study of RSR-13 (n = 6) versus 0.45% saline (n = 12) was conducted, after an RSR-13 dose-escalation study (n = 4). Drug was administered as a preocclusion bolus followed by a continuous infusion for the duration of the experiment (5 hours). Brain oxygen was measured continuously with the use of a Clark oxygen electrode. Infarct size was measured at 5 hours after occlusion with computer-assisted volumetric analysis. The drug treatment group had consistently higher mean brain oxygen tension than controls (33 +/- 5 and 27 +/- 6 mm Hg, respectively) and significantly smaller infarcts (21 +/- 9% versus 33 +/- 9%, respectively, P < .008). We observed an inverse relationship between the dose response of RSR-13 (the shift in the hemoglobin/oxygen dissociation curve) and infarct size. These results are evidence that allosteric hemoglobin modification is protective to the brain after acute focal ischemia, providing a new opportunity for neuroprotection and raising the possibility of enhancing the protective effect of thrombolysis and ion channel blockade.Keywords
This publication has 13 references indexed in Scilit:
- Perfluorocarbons: recent developments and implications for neurosurgeryJournal of Neurosurgery, 1996
- Thrombolytic Therapy with Streptokinase in Acute Ischemic StrokeNew England Journal of Medicine, 1996
- RSR13: Effects on tumor oxygenation and response to therapyDrug Development Research, 1996
- Increased radiation response of FSaII fibrosarcomas in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinityRadiation Oncology Investigations, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in ratsBiochemistry, 1992
- Results of a prospective randomized trial for treatment of severely brain-injured patients with hyperbaric oxygenJournal of Neurosurgery, 1992
- Hemorrhagic Hypotension After Brain Injury Causes an Early and Sustained Reduction in Cerebral Oxygen Delivery Despite Normalization of Systemic Oxygen DeliveryPublished by Wolters Kluwer Health ,1992
- Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agentsJournal of Medicinal Chemistry, 1991
- Design, synthesis, and testing of potential antisickling agents. 1. Halogenated benzyloxy and phenoxy acidsJournal of Medicinal Chemistry, 1982